glp-1 weight loss wegovy drugs may be misused by patients with eating disorders: Study Comparing Ozempic, Wegovy and Other

Lancet 382:339352 Thomas MC, Cooper ME, Zimmet P (2016) Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease

6A), as reported in mice with global FGF21 deletion 31

Certain patients, such as those with a hereditary eye condition called Lebers disease, should avoid B12 injections altogether, as these may worsen symptoms

For type 2 diabetes , NICE guideline NG28 recommends considering GLP-1 agonists as an option when: Triple therapy with metformin and two other oral drugs is ineffective, not tolerated, or contraindicated The person has a BMI 35 kg/m (or 32.5 kg/m in people of South Asian or related ethnicity) and specific psychological or medical problems associated with obesity Insulin therapy would have significant occupational implications or weight loss would benefit other obesity-related comorbidities Treatment should be continued only if there is a beneficial metabolic response (HbA1c reduction of at least 11 mmol/mol [1.0%] and weight loss of at least 3% of initial body weight at 6 months)

Glycyl-l-histidyl-l-lysine prevents copper- and zinc-induced protein aggregation and central nervous system cell death in vitro